Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 461-466

  Labropoulos, Stefanos V ^a   Fletcher, Jonathan A ^b   Oliveira, Andre M ^b   Papadopoulos, Savvas ^a   Razis, Evangelia D ^a  

^a HYGEIA HOSPITAL   (Greece)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dermatofibrosarcoma protuberans; Fluorescence in situ hybridization; Imatinib mesylate; Platelet derived growth factor; Target therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD34 ANTIGEN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IMATINIB; MESNA; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE KINASE INHIBITOR; VIMENTIN;

ADULT; ANEMIA; ARTICLE; CANCER REGRESSION; CASE REPORT; CHROMOSOME ABERRATION; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; EDEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NODULE; METASTASIS; NEUTROPENIA; PDGFB GENE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SOFT TISSUE TUMOR;

CHROMOSOME ABERRATIONS; DERMATOFIBROSARCOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MUTATION; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 15944412898     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00014     Document Type: Article

References (14)

1. Weiss SW, Goldblum JR (editors). Enzinger and Weiss's Soft Tissue Tumors, 4th edn. St Louis, MO: Mosby; 2001.
2. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, et al. The dermatosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB, Cancer Res 1999; 59:3719-3723.
3. O'Brien KP, Seroussi E, Dal Chil P, Sciot R, Mandahl N, Fletcher JA, et al. Various regions within the alpha-helical domain of COL1A1 gene are fused to the second exon of the PDGF gene in dermatosarcomas and giant cell fibroblastomas. Genes Chromosomes Cancer 1998; 23:187-193.
4. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growth-inhibitory effect of STI-571 on cells transformed by the COL1A1/PDGF rearrangment. Int J Cancer 2001; 92:354-360.
5. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Chin P, Buchdunger E, et al. Growth inhibition of dermatosarcoma protuberans tumors by the platelet derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61:5778-5783.
6. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatosarcoma protuberans. J Clin Oncol 2002; 20:3586-3591.
7. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatosarcoma protuberans. Int J Cancer 2002; 100:623-626.
8. Hsi BL, Xiao S, Fletcher JA. Chromogenic in situ hybridization and FISH in pathology. Methods Mol Biol 2002; 204:343-351.
9. Awan RA, Dixon RH, Antonescu CR, Maki RG, Patients with metastatic sarcoma arising from dermatosarcoma protuberans (DFSP) may respond to imatinib. Proc Am Soc Clin Oncol 2001; 21:abstr 1637.
10. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 258: 1421-1423.
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 2001; 293:876-880.
12. Heinrich MG, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
13. McArthur G. Molecular targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004; 31(2 suppl 6):30-36.
14. Blay JY, Berthaud P, Perol I, Ray-Coquard I, Bui B, Duffaud F, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004; 24:abstr 9006.